Barclays has opened coverage on Regeneron Pharmaceuticals with an Overweight rating and a price objective of $923, concluding that the market does not fully reflect the drugmaker’s near- and medium-term profit potential. The brokerage singled out Dupixent as the main driver of underestimated revenue growth and pointed to a range of pipeline opportunities that could support further upside.
Describing Dupixent as effectively "a pipeline in a product," Barclays said the drug’s expansion across additional indications and deeper penetration within its approved uses has sustained double-digit annual sales increases nearly nine years after initial approval. The firm expects upcoming new indications - specifically chronic obstructive pulmonary disease and chronic spontaneous urticaria - to underpin the next phase of Dupixent’s growth even as competitive pressures rise. Barclays also noted that intellectual property protections for Dupixent could extend into the mid-2030s.
On Regeneron’s ophthalmology business, Barclays acknowledged investor concerns about potential erosion of Eylea market share from biosimilars but argued those worries are overemphasized. The brokerage pointed out that the higher-dose formulation, Eylea HD, represented about half of total Eylea sales exiting 2025, and it expects the transition toward the higher-dose option to continue. That shift, Barclays said, could offset some of the competitive pressure facing standard-dose ophthalmology products beginning in 2026.
Beyond eye disease, Barclays highlighted Regeneron’s programs in immunology and oncology. The firm identified Lynozyfic as an opportunity in multiple myeloma and suggested that the multiple myeloma market could exceed $10 billion as treatment paradigms move toward longer-term disease management. Barclays expects Lynozyfic to win share through a combination of higher efficacy and simpler dosing compared with alternatives.
Additional near-term clinical catalysts were also flagged. Barclays said late-stage data due over the next two years for the combination of fianlimab and Libtayo in metastatic melanoma, along with potential broader cancer indications, could provide meaningful updates for investors. The firm further cited programs aimed at the complement C5 pathway and factor XI as potential sources of long-term growth.
Balancing the clinical picture with financial resources, Barclays noted Regeneron has approximately $20 billion in cash and generates annual cash flow in excess of $5 billion. Combined with a broad clinical pipeline, the brokerage concluded that the current valuation does not adequately capture the company’s growth runway.
Separately, product and portfolio evaluators referenced in the original report evaluate Regeneron alongside many other companies using automated tools that analyze financial and market metrics. Those tools, the report said, are used to identify stocks with attractive risk-reward profiles and have previously highlighted companies that delivered substantial gains.
Sector implications: Barclays’ analysis touches both the pharmaceutical and biotech sectors, and has implications for equity investors assessing valuation vs. pipeline risk in healthcare stocks. Ophthalmology markets and oncology/immunology franchises are specifically affected themes.